Amarin Stock (NASDAQ:AMRN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.46

52W Range

$0.43 - $1.37

50D Avg

$0.54

200D Avg

$0.71

Market Cap

$182.44M

Avg Vol (3M)

$1.26M

Beta

1.93

Div Yield

-

AMRN Company Profile


Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

IE

Employees

275

IPO Date

Apr 01, 1993

Website

AMRN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Product$285.30M$366.51M$580.32M
Licensing And Royalty$21.61M$2.68M$2.87M

Fiscal year ends in Dec 23 | Currency in USD

AMRN Financial Summary


Dec 23Dec 22Dec 21
Revenue$285.30M$369.19M$583.19M
Operating Income$-67.59M$-92.34M$22.28M
Net Income$-59.11M$-105.80M$7.73M
EBITDA$-67.59M$-90.26M$25.14M
Basic EPS$-0.15$-0.26$0.02
Diluted EPS$-0.15$-0.26$0.02

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 30, 24 | 8:50 PM
Q2 24Jul 31, 24 | 12:28 PM
Q1 24May 01, 24 | 12:00 AM

Peer Comparison


TickerCompany
ABBVAbbVie Inc.
AZNAstraZeneca PLC
MRKMerck & Co., Inc.
GSKGSK plc
AMGNAmgen Inc.
JNJJohnson & Johnson
GILDGilead Sciences, Inc.
BIIBBiogen Inc.
BMYBristol-Myers Squibb Company
NVSNovartis AG
SNYSanofi